AR124123A1 - Anticuerpos anti-cd25 - Google Patents

Anticuerpos anti-cd25

Info

Publication number
AR124123A1
AR124123A1 ARP210103224A ARP210103224A AR124123A1 AR 124123 A1 AR124123 A1 AR 124123A1 AR P210103224 A ARP210103224 A AR P210103224A AR P210103224 A ARP210103224 A AR P210103224A AR 124123 A1 AR124123 A1 AR 124123A1
Authority
AR
Argentina
Prior art keywords
seq
cdr1
cdr2
cdr3
cdrs
Prior art date
Application number
ARP210103224A
Other languages
English (en)
Spanish (es)
Inventor
Daniel Olive
Armand Bensussan
Jrme Giustiniani
Anne Marie-Cardine
Arnaud Foussat
Jemila Houacine
Original Assignee
Inst Nat Sante Rech Med
Inst Jean Paoli & Irene Calmettes
Alderaan Biotechnology
Centre Nat Rech Scient
Univ D’Aix Marseille
Univ Paris
Univ Paris Val De Marne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Inst Jean Paoli & Irene Calmettes, Alderaan Biotechnology, Centre Nat Rech Scient, Univ D’Aix Marseille, Univ Paris, Univ Paris Val De Marne filed Critical Inst Nat Sante Rech Med
Publication of AR124123A1 publication Critical patent/AR124123A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP210103224A 2020-11-20 2021-11-19 Anticuerpos anti-cd25 AR124123A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20306424 2020-11-20

Publications (1)

Publication Number Publication Date
AR124123A1 true AR124123A1 (es) 2023-02-15

Family

ID=73698744

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103224A AR124123A1 (es) 2020-11-20 2021-11-19 Anticuerpos anti-cd25

Country Status (9)

Country Link
US (1) US20240002522A1 (enExample)
EP (1) EP4247497A1 (enExample)
JP (1) JP2023550446A (enExample)
KR (1) KR20230118108A (enExample)
CN (1) CN116917318A (enExample)
AR (1) AR124123A1 (enExample)
AU (1) AU2021380966A1 (enExample)
CA (1) CA3199006A1 (enExample)
WO (1) WO2022106665A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023222886A1 (en) 2022-05-20 2023-11-23 Depth Charge Ltd Antibody-cytokine fusion proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US61816A (en) 1867-02-05 bunbab and a
US96973A (en) 1869-11-16 saxton
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
ES2252261T3 (es) 2000-06-28 2006-05-16 Glycofi, Inc. Metodos para producir glicoproteinas modificadas.
CA2430013C (en) 2000-11-30 2011-11-22 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
PL2602323T3 (pl) 2007-06-01 2018-06-29 Open Monoclonal Technology, Inc. Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
US11879014B2 (en) * 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) * 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
US10752691B2 (en) * 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
EP3972997A1 (en) * 2019-05-20 2022-03-30 Institut National de la Santé et de la Recherche Médicale (INSERM) Novel anti-cd25 antibodies

Also Published As

Publication number Publication date
CA3199006A1 (en) 2022-05-27
JP2023550446A (ja) 2023-12-01
CN116917318A (zh) 2023-10-20
EP4247497A1 (en) 2023-09-27
KR20230118108A (ko) 2023-08-10
US20240002522A1 (en) 2024-01-04
AU2021380966A1 (en) 2023-06-22
WO2022106665A1 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
PE20030846A1 (es) Anticuerpos para cd40
JP2019201643A5 (enExample)
JP2017052784A5 (enExample)
RU2013153527A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
PE20221511A1 (es) Anticuerpos anti-ly6g6d y metodos de uso
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
IL299221A (en) Cd3 binding antibodies
AR109715A1 (es) Anticuerpos anti-cd27
RU2014122990A (ru) Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
IL280487B2 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
IL250289B2 (en) Antibodies against angiopoietin-like 4 and methods of use
PE20181051A1 (es) Anticuerpo anti-epha4
AR123306A1 (es) Anticuerpos fgfr3 y métodos de uso
FI3515947T3 (fi) Uudet tekijän XI vasta-aineet ja niiden käyttökohteet
FI4031569T3 (fi) Kantasolutekijän vasta-aineet ja niiden käyttömenetelmät
AR124123A1 (es) Anticuerpos anti-cd25
JP2022517216A5 (enExample)
IL277899B1 (en) Methods and compositions for treating yellow fever
PE20212269A1 (es) Anticuerpos anti-trem1 y metodos relacionados
AR129472A1 (es) Anticuerpos anti-bcma
AR126971A1 (es) Composiciones y métodos para tratar el síndrome de qt largo
AR130641A1 (es) Anticuerpos anti-cd28
AR129565A1 (es) Anticuerpos igf1r

Legal Events

Date Code Title Description
FB Suspension of granting procedure